Stock Market Update - March 31, 2026
Today's stock market saw some significant movers. Here's a breakdown of 5 stocks that caught our attention:
1. APLS - Apellis Pharmaceuticals, Inc.
Price: $40.23 | Change: +135.40% ($23.14)
APLS soared an incredible 135.40% around April 1, 2026, following a major acquisition announcement that sent its stock rocketing. Apellis Pharmaceuticals saw its shares surge after pharmaceutical giant Biogen (BIIB) revealed it was acquiring the company in an all-cash deal valued at approximately $5.6 billion. Biogen offered $41 per share, which represented a substantial premium of about 140% over Apellis' closing price just days before the announcement.
Beyond the upfront cash, Apellis shareholders also stand to receive additional payments tied to the future sales performance of SYFOVRE, one of their key medicines. This strategic move grants Biogen access to Apellis' two approved medicines, SYFOVRE and EMPAVELI, which collectively generated $689 million in net sales in 2025. Biogen's aim is to significantly enhance its growth in immunology and rare diseases, making this acquisition a notable play in the biopharmaceutical sector.
2. AMPGZ - Amplitech Group, Inc. Series B Right
Price: $0.12 | Change: +112.77% ($0.0636)
AMPGZ:NASDAQ just soared with an impressive 112.77% gain. This significant movement for Amplitech Group, Inc. Series B Right is largely driven by a series of positive announcements from its parent company, AmpliTech Group, Inc. (AMPG), specifically related to its rapidly advancing 5G commercial pipeline.
The excitement stems from AMPG announcing that its flagship Massive MIMO 64T64R radio has achieved crucial O-RAN compliance, a key milestone for its 5G technology. Adding to the momentum, the company revealed initial production shipments exceeding $20 million under a $40 million Letter of Intent, alongside new funded purchase orders for another large LOI.
These operational advancements were reinforced by strong financial performance: AmpliTech Group reported a substantial 165% year-over-year revenue growth in fiscal year 2025, reaching $25.2 million, and reaffirmed ambitious revenue guidance of at least $50 million for fiscal year 2026. This progress in the burgeoning 5G infrastructure market, combined with robust financial projections, has clearly boosted investor confidence.
3. UBXG - U-BX Technology Ltd.
Price: $3.34 | Change: +112.74% ($1.77)
UBXG:NASDAQ (U-BX Technology Ltd.) experienced an impressive 112.74% surge around April 1, 2026. This significant jump was primarily driven by positive analyst forecasts and new price targets issued in late March. Analysts projected a strong outlook for the stock, setting an average price target of approximately $3.79, a substantial increase from its previous trading price of around $1.70.
This bullish sentiment from experts likely acted as a powerful catalyst, sparking increased investor interest and pushing the share price from the mid-$1 range to about $3.34. What makes this move particularly noteworthy is how this strong analyst optimism managed to override some existing bearish signals and declining trends noted by other market analyses during the same period, underscoring the significant impact of positive expert opinion on a stock's short-term performance.
4. MASK - 3 E Network Technology Group Ltd Class A Ordinary Shares
Price: $2.27 | Change: +83.06% ($1.03)
MASK:NASDAQ just made an eye-popping 83.06% gain!
The primary driver behind this recent climb for 3 E Network Technology Group Ltd (MASK) is a significant rebound following its 25-for-1 reverse stock split, which took effect on March 16, 2026. This move mechanically increased the per-share price and reduced the number of shares. After reportedly dropping to $1.24 just before its rebound, the stock saw a substantial surge, including a 33.87% jump on March 31, 2026, reflecting a market recalibration and positive sentiment.
Beyond the split, 3 E Network has also made several strategic announcements earlier this year that likely fueled investor interest. These include securing a $20 million Equity Line of Credit, establishing its 'Nordic Compute Gateway' project in Finland to expand AI infrastructure, and appointing a new Vice President to strengthen technology leadership. These initiatives in the AI and IT solutions space seem to be contributing to renewed optimism and the stock's recovery post-split.
5. ELAB - PMGC Holdings Inc.
Price: $5.99 | Change: +68.26% ($2.43)
ELAB saw an impressive 68.26% gain, driven by a wave of positive news from PMGC Holdings Inc. The company announced robust 2025 annual results, including a substantial 43% increase in total assets, boosted by strategic acquisitions in precision manufacturing and industrial packaging sectors.
A major catalyst came from its biopharmaceutical subsidiary, Northstrive Biosciences. The company received positive preliminary FDA feedback for EL-22, an oral probiotic designed to preserve muscle mass for patients on GLP-1 weight loss treatments, paving the way for a Phase 2 clinical trial. This news, along with an amended licensing agreement for its biopharma candidates, sparked a pre-market surge of over 100% on a single day. Adding to the momentum, PMGC's manufacturing subsidiaries also secured a significant five-year aerospace agreement and gained key defense contracting eligibility.
What’s interesting here is the dual-engine growth from both established manufacturing sectors and the high-potential biopharmaceutical space, with positive developments spanning FDA progress and new contracts contributing to investor enthusiasm.
This analysis was generated using AI and real-time stock data. Always do your own research before making investment decisions.